Skip to main content
. 2022 Nov 8;10(11):e005531. doi: 10.1136/jitc-2022-005531

Figure 1.

Figure 1

Tertiary lymphoid structures (TLS) in NSCLC and its relationship with DFS. (A) High-maturation of TLS, dense lymphocytic aggregates (CD3+, CD20+) with follicular dendritic cells (CD21+) ×10; (B) Low-maturation of TLS, dense lymphocytic aggregates (CD3+, CD20+) without follicular dendritic cells (CD21-) ×10; (C) Comparison of TLS maturity (p<0.001) and TLS abundance (p=0.043) under different treatments; (D) Kaplan-Meier analysis of DFS curve of patients with the TLS maturity in the neoadjuvant chemoimmunotherapy group (p=0.005); (E) DFS curve of patients with the TLS maturity in the neoadjuvant chemotherapy group (p<0.001); (F) DFS curve of patients with the TLS maturity in the treatment naïve group (p=0.020); (G) DFS curve of patients with the TLS abundance in the neoadjuvant chemoimmunotherapy group (p=0.035); (H) DFS curve of patients with the TLS abundance in the neoadjuvant chemotherapy group (p=0.003); (I) DFS curve of patients with the TLS abundance in the treatment naïve group (p=0.047). NSCLC, non‒small cell lung cancer.